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In order to apply human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) to
regenerative medicine, the cells should be produced under restricted conditions conforming to GMP
guidelines. Since the conventional culture system has some issues that need to be addressed to achieve this
goal, we developed a novel culture system. We found that recombinant laminin-511 E8 fragments are useful
matrices for maintaining hESCs and hiPSCs when used in combination with a completely xeno-free (Xf)
medium, StemFitTM. Using this system, hESCs and hiPSCs can be easily and stably passaged by dissociating
the cells into single cells for long periods, without any karyotype abnormalities. Human iPSCs could be
generated under feeder-free (Ff) and Xf culture systems from human primary fibroblasts and blood cells,
and they possessed differentiation abilities. These results indicate that hiPSCs can be generated and
maintained under this novel Ff and Xf culture system.
H
uman embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) hold promise as tools for
regenerative medicine. Recently, several reports have discussed the potential use of stem cells in clinical
applications. Geron has initiated treatment of neural disease using neuronal cells derived from hESCs.
Advanced Cell Technologies is making efforts to treat eye diseases with ESC-derived cells1. This approach
involves the production of retinal pigment epithelium from hESCs that are then transplanted into patients.
Regenerative medicine using stem cells, particularly pluripotent stem cells, will certainly advance over the coming
years as new discoveries are made.
Researchers usually use feeder cells and serum-containing medium in conventional culture systems for hESCs
and hiPSCs2,3. Murine-derived feeder cells are widely used to maintain hESCs and hiPSCs. Human-derived feeder
cells are also used for hESC/iPSC culture; however, in some cases, these cells have proven unsuitable for stem cell
maintenance4,5. The feeder cell preparation requires significant time and effort. Fetal bovine serum (FBS)-con-
taining medium is normally used for the culture of feeder cells. The reduction or complete removal of serum and
animal-derived products is required to satisfy Standard for Biological Ingredients. Moving towards feeder-free
culture systems for hESCs and hiPSCs would represent a significant improvement over conventional culture
systems.
To address these issues, we sought to develop a novel culture system applicable for human stem cell main-
tenance and hiPSC derivation. Feeder-free (Ff) and xeno-free (Xf) conditions appear to be acceptable for cul-
turing hESCs and hiPSCs. Various matrices can be used to replace feeder cells, such as Matrigel6–8, CELLstart9,10,
recombinant proteins11–13 and synthetic polymers14,15. Xeno-free media are also available commercially, including
TeSR2, NutriStem and Essential E8 medium13, among others. Although we examined most of these materials with
respect to whether the hESCs and hiPSCs could be stably and efficiently cultivated in our laboratory, we were
unable to identify an efficacious combination of matrix and medium.
It has previously been reported that laminin-511 supports the stable culture of hESCs and hiPSCs11. Recently, a
shorter fragment of laminin-511, referred to as the laminin-511 E8 fragment (LN511E8), was also shown to
efficiently maintain hESCs and hiPSCs12. Recombinantly expressed LN511E8 (rLN511E8) is isolated more easily,
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matrix for our novel culture system for hESCs and hiPSCs. Next, we
examined whether a new xeno-free medium, StemFitTM, could be
used for our novel culture system with rLN511E8.
Employing these materials, we successfully developed a novel cul-
ture system for hESCs and hiPSCs using rLN511E8 and StemFitTM
that is easy to use, expandable and reproducible, as clinical-grade
hiPSCs must be manufactured according to Standard Operating
Procedures (SOPs) in order to meet Cell Processing Center (CPC)
standards.
Human ESCs and iPSCs were stably passaged for long periods by
dissociating the cells into single cells. Moreover, hiPSCs were suc-
cessfully established from primary fibroblasts, peripheral blood and
cord blood under these conditions using episomal vectors16,17. These
Ff-hiPSCs displayed the capacity to differentiate into various types of
somatic cells, including all three germ layers. These results indicate
that Ff-hiPSCs are suitable for manufacturing in a CPC setting, and
should prove useful for future research and clinical applications.
Results
Development of a novel culture system for hiPSCs. To develop
feeder-free (Ff) and xeno-free (Xf) hiPSC culture conditions, we
tested Matrigel, CellStart and the recombinant laminin-511 E8
fragment (rLN511E8) as coating matrices12. H9 hESCs were disso-
ciated into single cells and plated onto the coated culture plates. The
hESCs efficiently formed colonies on rLN511E8 but not on the other
matrices (Figure S1A). We therefore selected rLN511E8 as the
coating matrix for our system. Using rLN511E8, we attempted to
cultivate hiPSCs using a variety of commercially available Xf-
medium (Figure S1B). TeSR2 did not support the maintenance of
hiPSCs (32R118) on rLN511E8. When we used NutriStem, the hiPSCs
formed flattened colonies. Although the mixture of TeSR2 and
NutriStem supported hESC-like colony formation, the morphology
was not good (many granules were detected in cells). Since we were
unable to obtain good results, we chose to try StemFitTM, a newly
developed Xf-medium for hiPSC culture from Ajinomoto Co., Inc.
Using StemFitTM, we obtained hiPSCs colonies similar to those
cultivated on feeder cells2 (Figure S1B).
We examined whether hESCs and hiPSCs, which were previously
established and maintained on feeder cells, can be cultivated under
the Ff and Xf conditions using rLN511E8 matrix and StemFitTM
(Figure 1A). After two or three passages, most of the hESCs and
hiPSCs adapted to the Ff and Xf culture conditions. The combination
of rLN511E8 and StemFitTM demonstrated efficacy for the hESCs and
hiPSC culture.
Human iPSCs were then dissociated into single cells and repro-
ducibly plated according to the exact cell number (Figure S2A), an
important consideration for standardizing culture conditions and
developing a reliable experimental design. The cells cultured on rLN-
511E8 became confluent within 8–10 days after plating (the average
fold change was 132 in each passage (Figure S2B)). The average
doubling time was 28.34 hours (Figure S2B). This period was faster
than that of hiPSCs cultivated on feeder cells2. Surprisingly, the high
cell viability permitted a split ratio of nearly 1:100 (Figure S2B).
Frozen stocks were prepared at 280uC using a standard slow-freez-
ing method, and were thawed in a 37uC water bath (Figure S2A).
We next examined whether the hES/iPSCs could be stably culti-
vated over long periods using the new culture conditions. We used
H9 hESCs, KhES1 hESCs and 201B7 hiPSCs for this experiment. The
cells were stably maintained for 20–30 passages, and markers of
pluripotency, such as Oct3/4 and TRA-1-60, were still detected
(Figures 1B and 1C). Passage number 54 of the 201B7 cells still
exhibited the ability to differentiate into all three germ layers in vitro
(Figure S2C). We concluded that our method is sufficient and effi-
cient for hESC and hiPSC culture. This culture system has already
been tested and showed similar results at several other laboratories in
Japan.
Establishment of hiPSCs under Ff and Xf conditions. Although we
successfully developed a highly efficient system for the culture of
hESCs and hiPSCs using rLN511E8 and StemFitTM, hiPSCs in-
tended for clinical application should be generated under similar
conditions. First, we attempted to establish hiPSCs from human
primary fibroblasts. Skin tissues were collected using biopsies, and
fibroblasts were generated from the skin tissues. Fibroblasts were
established under Xf conditions with medium containing 10% auto-
logous serum. The fibroblasts were electroporated with episomal
vectors containing reprogramming factors. Twenty to thirty days
after electroporation, hiPSC colonies were observed and selected to
establish feeder-free hiPSC (Ff-hiPSC) clones, 987A3 and 987A7
(Figure 2A). The morphology of the fibroblast-derived Ff-hiPSCs
was similar to that of 201B7 or H9 cells cultivated on rLN511E8.
The loss of episomal vectors was confirmed using a genomic PCR
analysis (Figure S3A).
The expression levels of markers of pluripotency were examined
using RT-PCR and immunostaining. The fibroblast-derived Ff-
hiPSC clones exhibited similar expression levels to those of 201B7
and H9 cells (Figures 2B and S3B). The expression levels of genes
related to pluripotency were similar in the cells cultivated on
rLN511E8 and feeder cells (Figure 2B). The fibroblast-derived Ff-
hiPSCs were stably passaged for long periods (Figure 2C) and had
normal karyotypes (Figure S3C).
Ff-hiPSCs were also established from peripheral blood-derived T-
cells, non-T-cells and cord blood. The morphology, marker gene
expression levels and stability for long-term culture of these cells
were similar to those of fibroblast-derived Ff-hiPSCs (Figures 2
and S3D).
The efficiency of Ff-hiPSC generation is summarized in Supple-
mental Table 1.
Differentiation capacity of Ff-hiPSCs. We examined whether Ff-
hiPSCs have the ability to differentiate into several types of somatic
cells. First, Ff-hiPSCs were cultivated on rLN511E8 with StemFitTM
in the absence of bFGF. The cells efficiently attached to rLN511E8-
coated plates and grew, exhibiting spontaneous differentiation. Two
weeks after differentiation, we confirmed the expression levels of
Sox17, a-smooth muscle actin (SMA) and bIII tubulin by immuno-
staining (Figure S4). Ff-hiPSCs were able to differentiate into all three
germ layers in vitro. Moreover, in the teratoma assays, Ff-hiPSCs
differentiated into various tissues of the three germ layers, includ-
ing gut-like epithelial tissue, cartilage and neural tissue (Figure 3A).
Another three Ff-hiPSC clones were also tested for the teratoma
assays. These results demonstrated that the Ff-hiPSCs are func-
tionally equivalent to iPSCs derived under feeder conditions2, and
have the potential to spontaneously differentiate into all three germ
layers both in vitro and in vivo.
The directed differentiation of hiPSCs has the potential to generate
various somatic cells for disease modeling, drug discovery, toxico-
logy, prediction of side effects, and eventually, transplantation ther-
apy. Therefore, we next examined whether Ff-hiPSCs could be
specifically induced to differentiate towards somatic cells of thera-
peutic interest.
Parkinson’s disease is characterized by the loss of dopaminergic
(DA) neurons; therefore, hiPSC-derived DA neurons may be good
sources for cell transplant therapy. Mature and functional DA neu-
rons have been produced through long-term culture of hiPSCs on
Matrigel19. We subjected Ff-hiPSCs to the neuronal differentiation
protocol with dual SMAD inhibition. Consequently, the Ff-hiPSCs
differentiated into DA neurons expressing tyrosine hydroxylase
(TH), bIII tubulin (Tuj1), Nurr1 and Foxa2 (Figure 3B). This experi-
ment was performed under Xf conditions. Therefore, these results
indicate that DA neurons can be successfully generated under Xf
conditions from human tissue samples obtained using Ff-hiPSCs
cultured without Matrigel.
www.nature.com/scientificreports
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As a second target lineage with therapeutic potential, we chose to
differentiate Ff-hiPSC into blood cells. Ff-hiPSCs were cultivated in a
low-binding cell culture plate to promote the formation of EB-like
spheres, which were sequentially treated with cytokines to invoke
blood cell differentiation, as described previously20. Erythroblasts,
macrophages and myeloid lineage cells were produced from Ff-
hiPSCs, as demonstrated using May-Grunwald-Giemsa staining
(Figure 3C).
The third target cells induced were insulin-producing cells. The
differentiation of Ff-hiPSCs into insulin-producing cells has been
reported previously21, and we made use of a similar protocol.
Consequently, insulin-producing cells were generated from Ff-
hiPSCs (Figure 3D). These results indicate that Ff-hiPSCs cultured
under Xf conditions have the ability to differentiate into specific
cells of interest using established in vitro induction protocols,
with some minor modifications to maintain the Xf conditions.
The efficiency and quality should be examined by the future
experiments.
Discussion
We developed a novel efficient culture system for hES/iPSCs without
feeder cells. Recombinant LN511E8 strongly supported hESC and
hiPSC culture for long periods. StemFitTM, a newly developed Xf-
medium, was the best medium for hESC and hiPSC culture with
rLN511E8. Under this novel culture system, hESCs and hiPSCs were
passaged by dissociating them into single cells. Moreover, hESC and
hiPSCs could be cryopreserved at 280uC by the slow-freezing
method. Ff-hiPSCs showed the ability to differentiate into several
somatic cell types, similar to conventional hiPSCs cultured on feeder
cells2.
The culture system using rLN511E8 has been reported previously
by Miyazaki et al.12. The authors also passaged hES/iPSCs by dissoci-
ating into single cells. Despite the basic idea is the same, we could
develop more efficient method using StemFitTM, achieving signifi-
cantly better attachment efficiency at 6 hours after plating
(Supplementary Table 2). Moreover, we confirmed the requirement
of the glutamic acid residue in the C-terminal tail of the laminin c1
Figure 1 | The feeder-free (Ff) and xeno-free (Xf) culture system for hES/iPS cells. (A) The morphology of hESCs (KhES1) and hiPSCs (32R1,
414C231, 585A131 and 606A131) cultivated on rLN511E8-coated cell culture plates with StemFitTM. Scale bar, 100 mm. (B) The growth curves of the hESCs
(H9 and KhES1) and hiPSCs (201B7) cultured under Ff and Xf conditions. Each dot represents a passage of cells. (C) The morphology of the indicated
passage numbers of 201B7 and H9 cells. The 201B7 and H9 cells at passage numbers p80 and p54, respectively, were immunostained for the
indicated pluripotency markers, followed by phase contrast imaging (Ph). Scale bar, 100 mm.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 3594 | DOI: 10.1038/srep03594 3
chain, substitution of which with glutamine abolishes the integrin
binding activity of LN511E824, in our culture method using an EQ
mutant of rLN511E8. The colony formation of 201B7 was not
observed on EQ mutant-coated plate (Figure S5).
Recently, the defined and simplified Xf medium, E8, was
reported13. The major difference in formulation between E8 and
StemFitTM is albumin. StemFitTM includes human albumin (E8 does
not include any albumins). Albumin has many biological and
Figure 2 | Establishment of iPS cell clones under the feeder-free (Ff) and xeno-free (Xf) culture system. (A) Human iPSCs established from skin-derived
primary fibroblasts (987A3 and 987A7), peripheral blood-derived T-cells (1027B3 and 1027B6), peripheral blood-derived non-T-cells (1120C7 and
1120C12) and cord blood cells (1156D2 and 1156D15) under the Ff and Xf culture system. Photographs were taken between passages p5 and p10. Scale
bar, 100 mm. (B) The gene expression levels of pluripotency markers as determined using RT-PCR. ‘‘LN’’ indicates that the cells were cultivated using the
Ff and Xf culture system reported herein. ‘‘Feeder’’ indicates cells that were cultivated on murine feeders with non-Xf medium. (C) The growth curve of
the feeder-free iPS cells cultured under Ff and Xf culture conditions.
www.nature.com/scientificreports
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physical roles. Thus, this factor may confer difference in perform-
ance between the both.
We are planning to build up a bank of hiPSCs for transplantation
therapy. The human leukocyte antigen (HLA) is a key factor that
mediates the immune-related rejection after transplantation. To min-
imize the immune system-related rejection, it is necessary to match
the HLA type of the donor and recipient. Matching the HLA type is
difficult because of the large number of HLA types present in each
individual. However, the Japanese population is relatively homogen-
eous compared to other populations, and it has been reported that
50–140 HLA-homozygous cell lines would match 90% of the
Japanese population17,22, a HLA-homozygous hiPSC bank would
therefore be a helpful resource for therapeutic application in Japan.
Ensuring the quality and safety of hiPSC are important for their
clinical application. Manufacturing hiPSCs should be performed in
the Cell Processing Center under the GMP guidelines. Our novel
hiPSC culture system is comparable to that of standard cell lines,
such as 293 cells or HeLa cells, making previously complex steps
more routine. Employing this easy to use, reproducible and expand-
able culture system, a large amount of clinical-grade hiPSC stock can
be made at early passage numbers at the same time. Moreover, the
procedures needed to establish and maintain Ff-hiPSCs should be
minimal and simple in the CPC. In order to apply Ff-hiPSCs for
clinical applications, it is necessary to reduce or completely eliminate
the use of animal-derived materials. To achieve this, we selected the
StemFitTM medium, which does not contain animal-derived materi-
als. This culture system is a promising method for manufacturing
clinical-grade hiPSCs. In addition, it is necessary to use defined cul-
ture system for the source of iPS cells, such as fibroblasts or blood
cells13,23.
Figure 3 | The differentiation capacity of the T-cell-derived feeder-free hiPSC clone, 1027B6 (p7–p12). (A) Hematoxylin and eosin staining of
teratomas showing representative derivatives of all three germ layers. Scale bar, 100 mm. (B) Differentiation into mesencephalic dopaminergic neurons
under Xf conditions. Photomicrographic images of immunostaining for Tuj1 (green), tyrosine hydroxylase (TH: red), Foxa2 or Nurr1 (blue) and DAPI
(white). Scale bar, 100 mm. (C) May-Grünwald-Giemsa staining of differentiated blood cells on day 16 showing hematopoietic precursor cells, myeloid
precursor cells, macrophages and erythroblasts. Scale bar, 100 mm. (D) Feeder-free hiPSCs differentiated into insulin-producing cells. After 23 days of
culture under the differentiation conditions, the cells were fixed and stained with Hoechst33342 (blue) and anti-insulin antibodies (magenta). Scale bar,
100 mm.
www.nature.com/scientificreports
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Ff-hiPSCs were generated from skin-derived fibroblasts and
blood-derived cells. Although the efficiency of Ff-hiPSC generation
was lower than that of iPSCs established on feeder cells, we were able
to obtain an adequate number of Ff-hiPSC clones. The cord blood
cells appeared to be more potent sources for Ff-hiPSC generation.
Almost all Ff-hiPSCs have differentiation potential, and can differ-
entiate into several kinds of somatic-type cells. These findings indi-
cate that the Ff-hiPSCs established under Ff and Xf conditions from
several types of somatic cells are similar to the hiPSCs established
using the conventional system with feeders.
In conclusion, the present results indicate that hiPSCs with equi-
valent growth and differentiation potential to feeder-grown hiPSCs
can be generated from various human tissue samples under Ff and Xf
conditions. Since this method is easy to use, expandable and repro-
ducible, it should prove valuable for generating clinical-grade hiPSCs
intended for drug screening and therapeutics, or even basic research
applications.
Methods
Production of laminin-511 E8. Recombinant LN511E8 were expressed in 293-F cells
(Life Technologies) with 6 3 His, HA and FLAG tags at the N-termini of the a5E8,
b1E8 and c1E8 chains, respectively, and were purified using affinity chromatography
with Ni-NTA resin and anti-FLAG antibody agarose, as described previously24.
rLN511E8 was also produced in cGMP-banked Freedom CHO-S cells (Life
Technologies) with an N-terminal 6 3 His tag on the a5E8 chain (iMatrix-511TM,
Nippi, Inc.). The cGMP-compatible rLN511E8 was purified using Ni-NTA affinity
chromatography and ion-exchange chromatography. cGMP-compatible rLN511E8
was manufactured in a controlled clean room (Nippi and Yokohama
Biopharmaceutical Research and Development Center).
Components of StemFitTM. In this study, we used newly developed medium
manufactured by Ajinomoto Co., Inc., Japan. StemFitTM contains twenty-one amino
acids (L-Alanine, L-Arginine, L-Asparagine, L-Aspartic Acid, L-Cysteine, L-Cystine,
L-Glutamic Acid, L-Glutamine, Glycine, L-Histidine, L-lsoleucine, L-Leucine, L-
Lysine, L-Methionine, L-Phenylalanine, L-Proline, L-Serine, L-Threonine, L-
Tryptophan, L-Tyrosine and L-Valine), ten vitamins (L-Ascorbic Acid, Cobalamin,
Biotin, Folic Acid, I-inositol, Niacinamide, D-Calcium Pantothenate, Pyridoxine
Hydrochloride, Riboflavin and Thiamine Hydrochloride), five trace minerals (Cupric
Sulfate, Ferric Sulfate, Ferric Nitrate, Zinc Sulfate and Sodium selenite) and growth
factors, including bFGF. All ingredients are highly defined or purified materials, and
none are derived from non-human animal sources. Large-scale manufacturing of
StemFitTM has been achieved in well-validated and -qualified factories in Japan.
Feeder-free culture system for hESCs and hiPSCs. The hESCs/iPSCs were cultivated
on rLN511E8-coated (0.5 mg/cm2) cell culture plates with StemFitTM and passaged via
dissociation into single cells using TrypLE Select (Life Technologies). Although this
approach is similar to a previously published method12, we separately developed a
single cell culture system for hESCs (H93 and KhES125) and hiPSCs (201B72 and
32R118). Before plating the cells, cell culture dishes or plates were coated with
rLN511E8 (0.5 mg/cm2). The rLN511E8 solution was diluted with PBS(2) and the
diluents were transferred to cell culture dishes or plates. The dishes or plates were
incubated for one hour in a CO2 incubator (37uC). The hESCs/iPSCs were dissociated
into single cells by treatment with 0.53 TrypLE Select (13 TrypLE Select diluted 1:1
with 0.5 mM EDTA/PBS(2)) for four minutes at 37uC. Since the cells remained
attached to the rLN511E8-coated plates, we aspirated the 0.53 TrypLE Select and
carefully washed the cells with PBS(2). The cells were scraped under the StemFitTM
and dissociated into single cells by pipetting the cells 10 times. The number of
dissociated single cells was counted using a Countess Automated Cell Counter (Life
Technologies). We typically plated 1.3 3 104 live cells into the rLN511E8-coated wells
of a 6-well cell culture plate (51.35 3 103 live cells/cm2). A Rock inhibitor (Y-27632,
final concentration 10 mM) was used only at the time of plating26. The next day, the
medium was changed to fresh StemFitTM without Y-27632. The medium was changed
every other day. Eight to ten days after plating, the cells reached 80–90% confluency
and were ready for the next passage. Frozen stocks of Ff-hiPSC were similarly
prepared as single cells and frozen in STEM-CELLBANKER (1 3 106 live cells/mL)
(Nippon Zenyaku Kogyo) at 280uC using a standard slow-freezing method.
Establishment of Ff-hiPSCs from fibroblasts and blood cells. Human primary
fibroblasts were derived from biopsied skin tissue samples. The fibroblasts were
established and expanded with DMEM containing 10% autologous human serum.
Using these fibroblasts, iPS cells were generated as described previously17. Briefly,
following electroporation of reprogramming factors with episomal vectors using the
Neon system (Life Technologies), the cells were plated on a non-coated cell culture
plate. iPS cells were induced by changing the medium to StemFitTM. Twenty to thirty
days after plating, iPS cell colonies were observed.
Blood cell-derived iPS cells were generated as described previously16. Briefly,
mononuclear cells were prepared from peripheral blood using the Ficoll-Paque
PREMIUM (GE Healthcare) separation method. The cells were electroporated with
episomal vectors using a Nucleofector 4D system (with P3 Primary Cell Kit, Lonza)
and plated on rLN511E8-coated cell culture plates. The iPSCs were induced by
changing the medium to StemFitTM. Twenty to thirty days after plating, iPS cell
colonies were observed. A similar method was used to generate Ff-hiPSCs from
human cord blood (provided by the RIKEN Bioresource Center Cell Bank). We
generated several clones of Ff-hiPSCs from each experiment.
The experimental protocols dealing with human subjects were approved by the
institutional review board at our institute (Kyoto University Graduate School and
Faculty of Medicine, Ethics Committee). Written informed consent was provided by
each donor.
Genomic PCR analysis of the integration of the episomal vectors. Purified genomic
DNA was used as a template to detect the remaining episomal vectors in the hiPSCs
using a PCR analysis. The episomal vectors were detected using the primer set for
EP4. The EP4 primer set was constructed in the EBNA1 region. The Fbx15 gene was
amplified with a primer set for Fbx as an internal control. The episomal vector,
pCXLE-EGFP, was used as a positive control (‘‘Plasmid’’). The primer sets are listed in
Supplementary Table 3.
Antibodies used for immunostaining. The antibodies used in this study included
anti-Oct3/4 (BD, 611202), -Nanog (R&D, AF1997), -SSEA4 (BD, 560073), -TRA-1-
60 (BD, 560071), -Sox17 (R&D, AF1924), -a-smooth muscle actin (SMA) (Dako,
M0851), -a-1-fetoprotein (AFP) (Dako, N1501) and -bIII tubulin (Millipore,
MAB1637) antibodies.
RNA isolation and reverse transcription. Total RNA purification and RT-PCR were
performed as described previously2,27–29. The expressions of Nanog, Sox2, Oct3/4,
Lin28, L-Myc, c-Myc, Klf4 and G3PDH were detected using the primer sets listed in
Supplementary Table 3.
In vitro differentiation. To examine whether Ff-hiPSCs spontaneously differentiate
into the three germ layers, the Ff-hiPSCs were cultivated with StemFitTM lacking bFGF
(StemFitTM-bFGF) for two weeks on rLN511E8-coated cell culture plates. The
differentiated cells were immunostained with the indicated antibodies.
Directed differentiation into dopaminergic neurons. Dopaminergic neurons were
induced from Ff-hiPSCs under xeno-free conditions. The dissociated Ff-hiPSCs were
plated on rLN511E8-coated plates at high density (7.5 3 105 cells/cm2; Day 0).
Glasgow minimum essential medium (GMEM, Life Technologies) was supplemented
with 8% Xeno-free knockout serum replacement (Life Technologies), sodium
pyruvate (SIGMA), 2-mercapto ethanol (Wako), MEM NEAA (Life Technologies),
500 nM of A-83-01 (Activin inhibitor, Wako), 100 nM of LDN193189 (BMP
inhibitor, STEMGENT) and 10 mM Y-27632 (Wako). To induce neural cells with a
ventral mesencephalic phenotype, 2 mM Purmorphamine (Wako) and 100 ng/mL of
FGF-8 (Wako) were added starting the next day. Starting on day 3, 3 mM CHIR99021
(GSK3b inhibitor, Wako) was also added. On day 12, the first passage was performed
with TrypLE CTS (Life Technologies), and the neural cells were replated on a fresh
rLN511E8 surface at the same density as on day 0. The basal medium was switched to
Neurobasal medium supplemented with Xeno-free B27 (Life Technologies), 200 mM
of ascorbic acid (SIGMA), 400 mM of dbc AMP (SIGMA), 2 ng/mL of GDNF (R&D),
20 ng/mL of BDNF (R&D) and 10 mM Y-27632. Throughout the neural induction
process, the medium was changed every day. On days 12, 20 and 28, the culture was
passaged onto a new rLN511E8 surface. Y-27632 was added to the medium on the day
of passage. Immunostaining was performed using anti-TH (Chemicon, AB152),
-Foxa2 (Santa Cruz, SC6554) and –Nurr1 (kindly provided by KAN Research
Institute) antibodies.
Directed differentiation into blood cells. Ff-hiPSCs were differentiated into blood
cells as described previously30 with some key modifications. Briefly, Ff-hiPSCs were
cultivated in Ultra Low Attachment 6-well cell culture plates (Corning) with
StemFitTM to prepare EB-like spheres. The spheres were subsequently used for blood
cell differentiation according to the established protocol20.
Directed differentiation into insulin-producing cells. Ff-hiPSCs were differentiated
into insulin-producing cells as described previously21. Briefly, human Ff-hiPSCs were
dissociated and plated on rLN511E8 and cultured with the reported factors required
for pancreatic differentiation. The dissociated cells were treated with 100 ng/ml of
activin A and 3 mM CHIR99021 for 24 hours, and then were treated with 100 ng/ml
of activin A and 1 mM CHIR99021 for four days. Next, the cells were cultured with
1 mM dorsomorphin (Calbiochem, San Diego, CA), 2 mM retinoic acid (Sigma, St.
Louis, MO) and 10 mM SB431542 (Sigma) for six days. Subsequently, the cells were
cultured with 10 mM forskolin, (Wako), 10 mM dexamethasone (Wako), 5 mM Alk5
inhibitor II (Calbiochem) and 10 mM nicotinamide (StemCell Technologies,
Vancouver, BC) for 12 days. Following the culture, the cells were fixed and stained
with Hoechst33342 (Life Technologies) and antibodies against insulin (Dako).
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